PRESS RELEASE
News
-
-
PRESS RELEASE
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options -
PRESS RELEASE
ESPG bond: More than 50% of bondholders have registered for written voting procedure – voting period is LIVE as of now
ESPG bondholders show strong participation in written voting procedure, aiming to reach quorum. Voting period now live with key decisions to be made, encouraging all to exercise their voting rights -
-
-
PRESS RELEASE
Original-Research: Borussia Dortmund GmbH & Co KGaA (von NuWays AG): BUY
Update on Borussia Dortmund GmbH & Co KGaA from NuWays AG highlights expected benefits from structural changes including Bundesliga broadcasting rights and new UCL format. Sponsorship upside and recent UCL success also contribute to positive outlook -
-
-
-
PRESS RELEASE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
BioNxt Solutions Inc. reports progress in toxicity and PK studies, advancing towards human comparative bioavailability studies. Development includes technology transfer, upscaling, & clinical sample prep for bioequivalence study
